Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study
Journal of the National Comprehensive Cancer Network · 2023-08 · 21 (8) · 805-812.e1
DOI: 10.6004/jnccn.2023.7022 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2023-08. Verfasst von John H Strickler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
HER2 amplification (HER2+) occurs in approximately 3% of patients with metastatic colorectal cancer (mCRC). Despite the recent addition of HER2-directed therapies to treatment recommendations in the NCCN Guidelines, until more recently there were no FDA-approved treatments. This study examined real-world treatment patterns in patients with HER2+ mCRC in the United States before and after the emerging awareness of HER2-directed therapies in 2018.
Methods
This was a retrospective observational study of patients with HER2+ mCRC from the GuardantINFORM database, which contains claims data for patients with Guardant360 genomic testing results. Patients were aged ≥18 years, were diagnosed with mCRC between January 2014 and September 2020, and had confirmed ERBB2 amplification via the blood-based Guardant360 test. Treatment patterns and real-world time to next treatment (rwTTNT) were evaluated.
Results
This study included 142 patients with a median age of 59 years; 31 (21.8%) patients with ERBB2 amplifications also had ERBB2 mutations. Treatment patterns were heterogeneous and evolved over time; before 2018, the most common regimen prescribed after detection of ERBB2 amplification was anti-VEGF therapy with or without chemotherapy (31.6%; n=25), and after 2018, HER2-directed therapies were the most commonly prescribed (36.5%; n=23). Median rwTTNT among the overall cohort was 8.4 months (95% CI, 6.5–10.0); rwTTNT was numerically longer in patients who received HER2-directed therapy compared with those who received non–HER2-directed therapies (11.0 months [95% CI, 6.3–12.3] vs 7.2 months [95% CI, 5.8–9.6]).
Conclusions
This real-world study of the largest clinically annotated dataset of patients with HER2+ mCRC showed that many patients do not receive HER2-directed therapy despite its inclusion in NCCN Guidelines, with heterogeneous treatment patterns suggesting that standard of care remains undefined and targeted therapy remains underutilized. Greater awareness of the unmet need in this patient population, together with new effective therapies, will facilitate strategies for improved, targeted treatment approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina.
- Seagen Inc., Bothell, Washington.
- Guardant Health, Inc., Redwood City, California.
- Division of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona.
Zitieren
APA
Strickler, J. H., Hsu, L. I., Wright, P., Stecher, M., Siadak, M. F., Palanca-Wessels, M. C., Yu, J., Zhang, N., Espenschied, C. R., Lang, K., & Bekaii-Saab, T. S. (2023). Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study. Journal of the National Comprehensive Cancer Network, 21(8), 805-812.e1. https://doi.org/10.6004/jnccn.2023.7022
Vancouver
Strickler JH, Hsu LI, Wright P, Stecher M, Siadak MF, Palanca-Wessels MC, et al. Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study. Journal of the National Comprehensive Cancer Network. 2023;21(8):805-812.e1. doi:10.6004/jnccn.2023.7022
BibTeX
@article{Strickler2023,
author = {Strickler, John H and Hsu, Ling-I and Wright, Phoebe and Stecher, Michael and Siadak, Muriel F and Palanca-Wessels, Maria Corinna and Yu, Junhua and Zhang, Nicole and Espenschied, Carin R and Lang, Kathryn and Bekaii-Saab, Tanios S},
title = {Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2023},
volume = {21},
number = {8},
pages = {805--812.e1},
doi = {10.6004/jnccn.2023.7022}
}
EUVIMED